SI-BONE, Inc. (SIBN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
Research Workspace
Put SIBN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 14% over the past year and decelerating.
View GrowthManagement screens strong on earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 46% in its worst 12-month stretch.
View RiskSIBN's Onyx launch has to keep compounding to justify the price. Revenue grew 14.5% year over year in the latest quarter. The company beat its earnings estimate by 38.5%. It trades at 5.1x sales versus a 2.8x peer median. This premium is 1.8x the peer average. The price reflects less growth than we forecast. A guidance cut would be a meaningful negative. Peer multiples imply a price about 6% below where it trades. This read is provisional. Our read remains intact.
Trailing returns as of 2026-11-04. SIBN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering SIBN (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for SIBN in the last 4 months.
Continue this research
Compare SIBN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SIBN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put SIBN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase worldwide revenue by ~15-16% in 2026
Reaffirms growth target, validates Onyx market potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $24.95
The last 12 months of price, then the range of analyst 12-month targets from today’s $24.95.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Increase worldwide revenue by ~15-16% in 2026
Q3 beat confirms revenue growth trajectory.

Advances: Expand physician base and commercial reach
FDA clearance expands commercial reach and physician base.

Advances: Expand physician base and commercial reach
Broadening growth supports expanding physician base and commercial reach.
